Broadest Immune Response from Nasal Spray Vaccine, NIH-Funded Study Finds

(The following release was published by the National Institute of Allergy and Infectious Diseases on August 16, 2011. Featured in the article is Dr. Daniel Hoft who gave a lecture titled “Romana’s Sign of the Times: Molecular Approaches for Protective T. cruzi Vaccines” during iCubed’s 2010 Vaccine Renaissance Conference.)

Children younger than 3 years old receive the same protective antibody response from the recommended two doses of licensed seasonal influenza vaccines regardless of whether the two doses are injected by needle, inhaled through a nasal spray or provided through one dose of each in any order, according to researchers funded by the National Institutes of Health. (Read more)